External validation of a model to predict risk of keratinocyte skin cancer after a renal transplantation in a Western European cohort.

Renal transplant recipients (RTRs) face an increased risk of developing keratinocyte skin cancer (KSC) due to their lifelong immunosuppressive drug use. Current recommendations call for 6- to 12-monthly skin examinations for all RTRs. To develop a more personalized screening procedure, Urwin, et al identified the most significant KSC risk factors in an Australian sample and developed a predictive index (PI) that stratifies patients into high-, medium- and low-risk groups. We have externally validated this PI and evaluated its geographic transportability to The Netherlands.